sorafenib
bayer
[]
adding tace to adjuvant sorafenib improved rfs and os in patients with hcc and pvtt. phase 2 results presented at asco gi 2023. #gi23 #gicsm #hccsm 
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.